Search Results - "Hecht JR"

Advancements in intratumoral therapies for liver tumors.

Authors: Raman SS Cutler NR Sramek JJ et al.

Source: Frontiers in oncology [Front Oncol] 2026 Feb 04; Vol. 16, pp. 1726128. Date of Electronic Publication: 2026 Feb 04 (Print Publication: 2026).

Publication Type: Journal Article; Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.

Authors: Eng C Lakhani NJ Philip PA et al.

Source: Targeted oncology [Target Oncol] 2025 May; Vol. 20 (3), pp. 519-530. Date of Electronic Publication: 2025 Mar 26.

Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

The extracellular matrix in inflammation and cancer.

Authors: Zhang W Xiang Y Lu C et al.

Source: Molecular biomedicine [Mol Biomed] 2026 Mar 06; Vol. 7 (1). Date of Electronic Publication: 2026 Mar 06.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Singapore Country of Publication: Singapore NLM ID: 9918283581406676 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-8651 (Electronic) Linking ISSN: 26628651 NLM ISO Abbreviation: Mol Biomed Subsets: MEDLINE

TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling.

Authors: Chao, Ying-Jui Wang, Hao-Chen Chen, Yu-Lun et al.

Source: Cellular Oncology (2211-3428). Apr2026, Vol. 49 Issue 2, p1-17. 17p.

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.

Authors: Hecht JR Park YS Tabernero J et al.

Corporate Authors: Hecht JR Park YS Tabernero J et al.

Source: Lancet (London, England) [Lancet] 2025 Nov 15; Vol. 406 (10517), pp. 2360-2370. Date of Electronic Publication: 2025 Oct 20.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Systems pharmacology approaches decipher the anti-cancer efficacy of ethnopharmacological agents in hepatocellular carcinoma.

Authors: Hao, Tingting Yang, Xiaonan Wang, Weibin et al.

Source: Scientific Reports. 12/17/2025, Vol. 15 Issue 1, p1-17. 17p.

Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting.

Authors: Dracham, Chinna Babu Bandanatham, Sweta Dumpala, Venkata Ravi Kiran et al.

Source: Scientific Reports. 11/5/2025, Vol. 15 Issue 1, p1-13. 13p.

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial

Authors: Nasca, Vincenzo Bergamo, Francesca Foltran, Luisa et al.

Source: BMC Cancer. 4/8/2025, Vol. 25 Issue 1, p1-11. 11p.

A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer.

Authors: Mao, Chenyu He, Ye Xu, Nong et al.

Source: Immunity, Inflammation & Disease. Aug2024, Vol. 12 Issue 8, p1-10. 10p.

Optimizing breast cancer treatment strategies through fractional-order dynamics: A computational modeling approach.

Authors: Jamadar, Irshad Sikandar Kumar, Krishna Khan, Ambareen et al.

Source: PLoS ONE. 5/14/2026, Vol. 21 Issue 5, p1-36. 36p.

Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy.

Authors: Li, Xiaoping Jabbarzadeh Kaboli, Parham Roozitalab, Ghazaal et al.

Source: Cellular Oncology (2211-3428). Apr2026, Vol. 49 Issue 2, p1-25. 25p.

Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.

Authors: Shi, Yuankai Wang, Xinshuai Pei, Zhidong et al.

Source: BMC Cancer. 3/17/2025, Vol. 25 Issue 1, p1-11. 11p.

Unveiling radiobiological traits and therapeutic responses of BRAF^V600E-mutant colorectal cancer via patient-derived organoids.

Authors: Mu, Peiyuan Mo, Shaobo He, Xingfeng et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 3/11/2025, Vol. 44 Issue 1, p1-19. 19p.

A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer.

Authors: Piermattei, Alessia De Luca, Roberto Peissert, Frederik et al.

Source: Journal of Ovarian Research. 8/26/2025, Vol. 18 Issue 1, p1-11. 11p.

Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting.

Authors: Wang, Qianqian Lv, Nan Xu, Dong et al.

Source: BMC Cancer. 7/24/2025, Vol. 25 Issue 1, p1-11. 11p.

Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT.

Authors: Sun, Chengyu Fan, Enguo Huang, Luqiao et al.

Source: PLoS ONE. 12/23/2024, Vol. 19 Issue 12, p1-19. 19p.

Deciphering of intra‐tumoural heterogeneity and the interplay between metastasis‐associated meta‐program and myofibroblasts in gastric cancer.

Authors: Wu, Xiongyan Jin, Zhijian Li, Baolong et al.

Source: Clinical & Translational Medicine. May2025, Vol. 15 Issue 5, p1-24. 24p.

Long-Term Oncological Outcomes of Granulocyte Colony-Stimulating Factor (G-CSF) Treatment in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.

Authors: Fischer, Oliver Wedel Justesen, Tobias Freyberg Gögenur, Dilara Seyma et al.

Source: Cancers. Apr2025, Vol. 17 Issue 8, p1313. 16p.

Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis.

Authors: Xie, Jun Mao, Qiu-yu Chen, Jun-hao et al.

Source: World Journal of Surgical Oncology. 4/9/2025, Vol. 23 Issue 1, p1-12. 12p.

Antibody therapies in glioblastoma: Overcoming microenvironmental barriers.

Authors: Dababneh, Moeen Fuad Muhammad, Faris Anad Shareef, Abdulkareem et al.

Source: Iranian Journal of Basic Medical Sciences. Mar2026, Vol. 29 Issue 3, p353-377. 25p.